Meeting
2014 ASCO Annual Meeting
Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
Authors
Andrea Necchi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Necchi , Luigi Mariani , Patrizia Giannatempo , Daniele Raggi , Elena Farè , Alfonso Marchianò , Flavio Crippa , Elena Togliardi , Maria Grazia Daidone , Alessandro M. Gianni , Roberto Salvioni , Filippo G. De Braud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Bladder Cancer
Clinical Trial Registration Number
2014-000557-36
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4592)
DOI
10.1200/jco.2014.32.15_suppl.tps4592
Abstract #
TPS4592
Poster Bd #
158B
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).
First Author: Milind M. Javle
Poster
2018 ASCO Annual Meeting
The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
First Author: Steven M. Horwitz
Poster
2018 ASCO Annual Meeting
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
First Author: Marjorie Glass Zauderer
Poster
2023 ASCO Annual Meeting
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
First Author: Andrew Peter Dean